In October 2019, FDA approved rivaroxaban (Xarelto—Janssen) for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients at risk of forming blood clots but not at high risk of bleeding.

Aina Abell

Trending Topics in Health-System Pharmacy

Preventing infectious disease transmission among health care workers and patients is a critical component of safe health care delivery in all settings.

Joey Sweeney, PharmD, BCPS

New data from an observational study conducted by CDC showed that first-line antibiotics were prescribed in only 50% of visits to retail clinics, emergency departments (EDs), urgent care centers, and offices for conditions such as pharyngitis, sinusitis, and acute otitis media.

Maria G. Tanzi, PharmDMaria G. Tanzi, PharmDMaria G. Tanzi, PharmDMaria G. Tanzi, PharmDMaria G. Tanzi, PharmD

The International Consensus Group recently updated the 2010 recommendations for managing nonvariceal upper GI bleeding (UGIB). The guidelines, which focus on resuscitation, assessment, bleed management, and secondary prophylaxis for recurrences, are presented as 15 statements with 38 corresponding recommendations based on the quality of evidence evaluated by voting participants.

Joey Sweeney, PharmD, BCPSJoey Sweeney, PharmD, BCPSJoey Sweeney, PharmD, BCPS